Massachusetts-based Intellia Therapeutics, Inc. (Nasdaq: NTLA) announced a non-dilutive senior secured term loan facility of up to USD 400 million with OrbiMed, structured to fund the commercial launch of its lead CRISPR gene editing therapy and advance its second late-stage program without shareholder dilution. The timing is directly tied to lonvoguran ziclumeran (lonvo-z), whose rolling biologics license application (BLA) to the US FDA is underway following positive Phase III data, with a US launch targeted for H1 2027.
The facility is structured in tranches over a five-year term. USD 75 million was funded at closing. Five additional tranches totaling up to USD 225 million are drawable at Intellia's option, subject to achievement of specified milestones linked primarily to lonvo-z. A further USD 100 million is available subject to mutual agreement between the parties. OrbiMed, a healthcare-focused investment firm, is the sole lender. Intellia raised around USD 180 million in a public equity offering earlier this year to extend its runway. The OrbiMed facility supplements that equity base with non-dilutive debt timed to commercial readiness activities.
Lonvo-z is an in vivo CRISPR/Cas9 therapy designed to permanently reduce plasma kallikrein by inactivating the KLKB1 gene via a single outpatient infusion, targeting hereditary angioedema (HAE) Types I and II. The Phase III HAELO trial reported an 87% reduction in mean monthly HAE attacks versus placebo at the primary endpoint, with full data showing a 91% reduction in moderate and severe attacks published in the New England Journal of Medicine in 2026. Intellia said the BLA rolling submission is expected to be completed in H2 2026. The second program, nexiguran ziclumeran (nex-z), a single-dose TTR gene-editing therapy for transthyretin amyloidosis, has resumed enrollment in its Phase III MAGNITUDE (cardiomyopathy) and MAGNITUDE-2 (polyneuropathy) trials after FDA clinical holds were lifted in early 2026; Intellia's CFO cited nex-z advancement as a secondary use of the facility's flexibility.